Therapies based on immune checkpoint inhibitors or anti-programmed cell death ligand 1 (PD-L1) drugs (e.g., nivolumab, ipilimumab, and pembrolizumab) have recently been approved by the FDA for use against CRC [7]. Here, CD274 is linked to colorectal carcinoma.